Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Hematologic Neoplasms
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Contact: Study coordinator (For more information at the NIH Clinical Center contact National Cancer Institute Referral Office) · 888-624-1937
Study leads
Christopher G Kanakry, M.D.
Principal Investigator
National Cancer Institute (NCI)